Revolution Medicines’ Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time Highs

by | Jun 1, 2026 | General

Revolution Medicines Inc. (NASDAQ:RVMD), on Sunday, unveiled breakthrough data showing its experimental pancreatic cancer pill more than doubled median overall survival compared with chemotherapy in a pivotal study.

The Survival Benefit

Daraxonrasib reduced the risk of death by 60% versus chemotherapy and more than doubled median overall survival in previously treated patients with metastatic pancreatic cancer harboring KRAS mutations, the company said.

The study also met its progression-free survival endpoint, with patients on daraxonrasib experiencing substantially longer disease control than those receiving standard treatment.

“These results will change how scientists, clinicians, and patients think about treatment for pancreatic cancer,” Brian M. Wolpin, Harvard’s ​Dana-Farber Cancer Institute and principal investigator for the trial said, adding that the results establish a new standard of care for patients whose disease has already been treated.


Read Also:

US Closes Loophole That Allowed Nvidia, AMD AI Chip Shipments To Chinese Firms Overseas

A Tough Cancer To Crack

Pancreatic cancer is among the deadliest forms of cancer, with five-year survival rates remaining low despite decades of research and drug development efforts.

Pancreatic cancer remains one of the deadliest cancers, with roughly 67,000 new U.S. cases and 53,000 deaths projected this year, according to the American Cancer Society.

A Rush For Access

U.S. cancer centers are moving to enroll patients in Revolution Medicines’ expanded access program, allowing eligible patients to receive daraxonrasib before a potential regulatory approval.

The FDA approved an expanded access program for daraxonrasib in May, weeks after Revolution Medicines reported positive Phase 3 results for the experimental pancreatic cancer treatment.

Shares of the company, which had risen 40% after the preliminary data was published in April, closed Friday up 1.9% at $157.48.

Benzinga Edge Rankings indicate that the Revolution Medicines stock has a Momentum score in the 97th percentile.


Read Also:

Their Duplex Has Been Fine. Their AI Stocks Have Been Incredible. Now They Are Debating Whether To ‘Sell Duplex For More Stocks?’

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Photo Courtesy: Tada Images on Shutterstock.com